Emerging Strategies and Advances in Treatment of Solid Tumors and Hematological Malignancies for Pra

Venue: Hyatt Regency Jersey City on the Hudson

Location: Jersey City, New Jersey, United States

Event Date/Time: Oct 06, 2012 End Date/Time: Oct 06, 2012
Report as Spam

Description

Statement of Need/Program Overview
This symposium is intended to improve care of cancer patients by accelerating adoption of new guidelines and evidence-based practice change. This symposium will focus on individualized therapy based on emerging agents currently in development, symptom control and management of toxicity issues, and practice guidelines and its impact on reimbursement issues. The format will include didactic lectures from known thought leaders, panel discussion and case presentation sessions, and ample opportunity for participant interaction with faculty. In-depth discussion of novel agents at various stages of clinical development will be given significant focus.

Target Audience
This symposium is directed primarily to oncologists/hematologists, radiation oncologists, surgical oncologists, researchers, registered pharmacists, registered nurses, urologists, physician assistants and nurse practitioners, fellows in training interested in new developments for treatment of various malignancies. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives
After completing this activity, the participant should be better able to:

Utilize histology in patient selection for integration of targeted therapy for lung cancer
Outline the optimal use of VEGF TKIs, EGFR TKI’s, EML4/ALK targeted agents based on biomarkers for lung cancer
Identify breast cancer patients for treatment with integration of novel cytotoxic agents including antibody-drug conjugates
Identify and utilize VEGF and EGFR based combination therapy for colorectal cancer
Explain the multidisciplinary approaches in the management of rectal cancer
Describe novel treatment options for pancreatic cancer and pancreatic neuroendocrine tumors
Utilize appropriate new therapeutic options for prostate cancer
Identify and utilize emerging treatment options for renal cell carcinoma
Utilize appropriate new therapeutic options in the management of malignant melanoma
Describe novel therapies for lymphomas
Appraise novel approaches in the treatment of relapsed multiple myeloma
Identify updates in the treatment of leukemia
Utilize appropriate supportive cancer care in the era of targeted therapy
Discuss practice guidelines and their impact on reimbursement issues in cancer treatment

Venue